Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ondine Biomedical, Inc. ( (GB:OBI) ) has issued an update.
Ondine Biomedical Inc. announced a correction to its total voting rights, stating that the company’s issued and fully paid share capital will consist of 518,366,964 Common Shares, rather than the previously stated 517,566,964. This adjustment is significant for shareholders as it affects the denominator used for calculating their interest in the company under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company focused on developing innovative medical solutions. The company is listed on the AIM market under the ticker OBI.
Average Trading Volume: 354,083
Technical Sentiment Signal: Buy
Current Market Cap: £66.64M
Find detailed analytics on OBI stock on TipRanks’ Stock Analysis page.